X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9532) 9532
Magazine Article (14) 14
Book Chapter (5) 5
Dissertation (4) 4
Publication (3) 3
Web Resource (3) 3
Book Review (1) 1
Conference Proceeding (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8583) 8583
quinazolines - therapeutic use (6002) 6002
female (4757) 4757
oncology (4072) 4072
male (4056) 4056
middle aged (3381) 3381
aged (2927) 2927
lung neoplasms - drug therapy (2838) 2838
antineoplastic agents - therapeutic use (2802) 2802
quinazolines - pharmacology (2479) 2479
adult (2438) 2438
carcinoma, non-small-cell lung - drug therapy (2304) 2304
gefitinib (2220) 2220
quinazolines - administration & dosage (2220) 2220
animals (2147) 2147
erlotinib hydrochloride (2009) 2009
receptor, epidermal growth factor - antagonists & inhibitors (1822) 1822
protein kinase inhibitors - therapeutic use (1732) 1732
treatment outcome (1704) 1704
cancer (1684) 1684
quinazolines - adverse effects (1653) 1653
antineoplastic combined chemotherapy protocols - therapeutic use (1644) 1644
chemotherapy (1592) 1592
erlotinib (1434) 1434
mutation (1326) 1326
cell line, tumor (1297) 1297
receptor, epidermal growth factor - genetics (1283) 1283
lung neoplasms - pathology (1222) 1222
mice (1181) 1181
lung neoplasms - genetics (1170) 1170
pharmacology & pharmacy (1139) 1139
aged, 80 and over (1122) 1122
growth-factor receptor (1008) 1008
antineoplastic agents - pharmacology (1004) 1004
egfr (957) 957
epidermal growth factor (951) 951
care and treatment (930) 930
tyrosine kinase inhibitor (895) 895
carcinoma, non-small-cell lung - genetics (887) 887
lung cancer (849) 849
carcinoma, non-small-cell lung - pathology (846) 846
breast neoplasms - drug therapy (820) 820
expression (815) 815
receptor, epidermal growth factor - metabolism (810) 810
adenocarcinoma - drug therapy (809) 809
disease-free survival (778) 778
research (769) 769
therapy (755) 755
lung cancer, non-small cell (733) 733
antineoplastic agents - adverse effects (691) 691
protein kinase inhibitors - pharmacology (690) 690
cell lung-cancer (683) 683
clinical trials as topic (652) 652
analysis (648) 648
survival (646) 646
prognosis (634) 634
neoplasm staging (630) 630
dose-response relationship, drug (622) 622
breast cancer (616) 616
tumors (616) 616
hematology, oncology and palliative medicine (612) 612
trastuzumab (607) 607
respiratory system (605) 605
medicine & public health (602) 602
antibodies, monoclonal, humanized (586) 586
cell proliferation - drug effects (582) 582
trial (578) 578
mutations (572) 572
apoptosis (571) 571
tyrosine (562) 562
drug therapy (555) 555
drug resistance, neoplasm (547) 547
lapatinib (532) 532
epidermal growth factor receptor (522) 522
lung neoplasms - mortality (520) 520
kinases (514) 514
non-small cell lung cancer (513) 513
signal transduction - drug effects (509) 509
quinazolines - pharmacokinetics (488) 488
neoplasms - drug therapy (479) 479
metastasis (476) 476
retrospective studies (476) 476
antineoplastic combined chemotherapy protocols - adverse effects (475) 475
apoptosis - drug effects (475) 475
antibodies, monoclonal - therapeutic use (473) 473
combination (473) 473
survival rate (470) 470
carcinoma, non-small-cell lung - mortality (462) 462
deoxycytidine - analogs & derivatives (461) 461
breast neoplasms - pathology (458) 458
prazosin - therapeutic use (453) 453
resistance (449) 449
adenocarcinoma (442) 442
receptor, erbb-2 - metabolism (440) 440
time factors (440) 440
disease progression (439) 439
health aspects (436) 436
open-label (436) 436
xenograft model antitumor assays (431) 431
survival analysis (429) 429
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8911) 8911
Japanese (251) 251
Chinese (142) 142
French (137) 137
German (126) 126
Spanish (57) 57
Italian (49) 49
Russian (43) 43
Hungarian (25) 25
Czech (19) 19
Polish (14) 14
Danish (11) 11
Portuguese (11) 11
Norwegian (7) 7
Dutch (6) 6
Romanian (4) 4
Hebrew (3) 3
Croatian (2) 2
Finnish (2) 2
Ukrainian (2) 2
Korean (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes & metabolism, ISSN 1262-3636, 2012, Volume 38, Issue 2, pp. 89 - 101
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering... 
Internal Medicine | Endocrinology & Metabolism | Linagliptine | Sitagliptin | Type 2 diabetes mellitus | Review | Clinical trial-DPP-4 inhibitor | Vildagliptine | Saxagliptine | Diabète de type 2 | Inhibiteur de la DPP-4 | Alogliptin | Sitagliptine | Linagliptin | Vildagliptin | Alogliptine | Revue générale | Essai clinique | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INITIAL COMBINATION THERAPY | RENAL IMPAIRMENT | DRUG-NAIVE PATIENTS | ADD-ON THERAPY | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN THERAPY | WEIGHT-GAIN | ELDERLY-PATIENTS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Purines - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - blood | Piperidines - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 02/2008, Volume 15, Issue 5, pp. 422 - 432
...) for growth factors, are among the best targets for this type of therapeutic approach. Two classes of compounds targeting RTKs are currently used in clinical practice... 
Monoclonal antibodies | Small molecules | Tyrosine kinase receptors | Targeted therapy | Cancer therapy | Tyrosine kinase inhibitors | targeted therapy | CHEMISTRY, MEDICINAL | GROWTH-FACTOR-RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | BCR-ABL | MONOCLONAL-ANTIBODY | CHRONIC MYELOID-LEUKEMIA | tyrosine kinase inhibitors | CELL LUNG-CANCER | BREAST-CANCER | tyrosine kinase receptors | cancer therapy | PHASE-II TRIAL | IN-VIVO | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | GASTROINTESTINAL STROMAL TUMORS | small molecules | monoclonal antibodies | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Bevacizumab | Antibodies, Monoclonal, Humanized | Sunitinib | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Lapatinib | Cetuximab | Gefitinib | Pyrroles - therapeutic use | Pyridines - therapeutic use | Clinical Trials as Topic | Piperazines - therapeutic use | Enzyme Inhibitors - therapeutic use | Imatinib Mesylate | Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Sorafenib | Indoles - therapeutic use | Benzamides | Trastuzumab | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10043, pp. 518 - 529
...) pathway inhibitors into the therapeutic armoury. Although some tumours such as renal cell carcinoma, ovarian and cervical cancers, and pancreatic neuroendocrine... 
Internal Medicine | PHASE-III TRIAL | ADVANCED HEPATOCELLULAR-CARCINOMA | BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | PANCREATIC NEUROENDOCRINE TUMORS | TYROSINE KINASE INHIBITOR | RECURRENT OVARIAN-CANCER | ANTI-ANGIOGENIC THERAPY | RESISTANT PROSTATE-CANCER | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Humans | Drug Resistance, Neoplasm | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Biomarkers, Tumor - metabolism | Female | Neovascularization, Pathologic - prevention & control | Molecular Targeted Therapy - methods | Receptor, TIE-2 - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Neoplasms - blood supply | Piperazines - therapeutic use | Angiopoietin-1 - antagonists & inhibitors | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Disease-Free Survival | Phthalazines - therapeutic use | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinolines - therapeutic use | Antimitotic agents | Pancreatic cancer | Melanoma | Neovascularization | Antineoplastic agents | Vascular endothelial growth factor | Prostate cancer | Cervical cancer | Drugs | Angiogenesis | Chemotherapy | Clinical trials | Oncology | Metastasis | Cancer therapies | Tumors | Cancer
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 10, pp. 931 - 932
Internal Medicine | MEDICINE, GENERAL & INTERNAL | STEVENS-JOHNSON-SYNDROME | Acetaminophen - adverse effects | Dacarbazine - adverse effects | Methylprednisolone - therapeutic use | Humans | Middle Aged | Dexamethasone - adverse effects | Male | Antineoplastic Agents - therapeutic use | Wound Healing | Anticonvulsants - adverse effects | Piracetam - therapeutic use | Stevens-Johnson Syndrome - therapy | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Antiemetics - adverse effects | Oxycodone - therapeutic use | Stevens-Johnson Syndrome - etiology | Anticonvulsants - therapeutic use | gamma-Globulins - therapeutic use | Analgesics, Opioid - therapeutic use | Stevens-Johnson Syndrome - diagnosis | Dexamethasone - therapeutic use | Glioblastoma - pathology | Piracetam - analogs & derivatives | Glioblastoma - complications | Glioblastoma - drug therapy | gamma-Globulins - administration & dosage | Dacarbazine - therapeutic use | Piracetam - adverse effects | Erythema - chemically induced | Analgesics, Opioid - adverse effects | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Erythema - diagnosis | Dacarbazine - analogs & derivatives | Oxycodone - adverse effects | Acetaminophen - therapeutic use | Proton Pump Inhibitors - adverse effects | Omeprazole - therapeutic use | Immunologic Factors - administration & dosage | Omeprazole - adverse effects | Proton Pump Inhibitors - therapeutic use | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Quinazolines - adverse effects | Drug Combinations | Immunologic Factors - therapeutic use | Methylprednisolone - administration & dosage | Medicine, Experimental | Toxic epidermal necrolysis | Medical research | Research
Journal Article
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 2017, Volume 24, Issue 16, pp. 1 - 16
... the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance... 
Tumor microenvironment | Fda-Approved drugs | Multitargeted drugs | Anticancer agents | Polypharmacology | Tyrosine kinase receptors | Oncogene addiction | CHRONIC MYELOGENOUS LEUKEMIA | CHEMISTRY, MEDICINAL | GROWTH-FACTOR-RECEPTOR | TARGETED-THERAPY | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | REGORAFENIB BAY 73-4506 | BCR-ABL INHIBITOR | anticancer agents | FDA-approved drugs | CELL LUNG-CANCER | tyrosine kinase receptors | oncogene addiction | polypharmacology | PHILADELPHIA-CHROMOSOME | COLORECTAL-CANCER | PHARMACOLOGY & PHARMACY | tumor microenvironment | GASTROINTESTINAL STROMAL TUMORS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Pyrazoles - therapeutic use | Pyridines - chemistry | Humans | Anilides - chemistry | Imidazoles - chemistry | Imatinib Mesylate - therapeutic use | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Niacinamide - chemistry | Phenylurea Compounds - chemistry | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Imidazoles - therapeutic use | Pyrroles - therapeutic use | Quinazolines - chemistry | Pyridazines - therapeutic use | Pyridines - therapeutic use | Piperidines - chemistry | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Receptor Protein-Tyrosine Kinases - metabolism | Imatinib Mesylate - chemistry | Neoplasms - drug therapy | Pyridazines - chemistry | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Pyrroles - chemistry | Indoles - therapeutic use | Neoplasms - pathology | Indoles - chemistry | Tyrosine | Cell proliferation | Drugs | Medical research | Phenotypes | Clinical trials | Kinases | Proteins | Inhibitors | Modulation | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9773, pp. 1276 - 1287
... to the identification of novel therapeutic targets. Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | SCLEROSTIN ANTIBODY | BONE-MINERAL DENSITY | CALCIUM-SENSING RECEPTOR | HUMAN OSTEOBLASTIC CELLS | OSTEOPROTEGERIN LIGAND | CATHEPSIN-K INHIBITOR | STRONTIUM RANELATE | VERTEBRAL FRACTURE | HEALTHY POSTMENOPAUSAL WOMEN | FRACTURE RISK | Wnt Proteins - drug effects | Vitamin D Deficiency - complications | Calcium - metabolism | Bone Morphogenetic Proteins - immunology | Humans | Middle Aged | Osteoporosis - diagnosis | Osteoporosis, Postmenopausal - metabolism | Antibodies, Monoclonal - therapeutic use | Osteoporosis - drug therapy | Wnt Proteins - metabolism | Biphenyl Compounds - therapeutic use | Osteoporosis - etiology | Bone Remodeling - drug effects | Antibodies, Monoclonal, Humanized | Osteoporosis - metabolism | Vitamin D Deficiency - therapy | Aged, 80 and over | Bone Resorption - metabolism | Diphosphonates - therapeutic use | Female | Benzodioxoles - therapeutic use | RANK Ligand - therapeutic use | Anabolic Agents - therapeutic use | Osteoporosis - prevention & control | Risk Assessment | Osteoporotic Fractures - prevention & control | Risk Factors | Bone Resorption - drug therapy | Bone Density Conservation Agents - therapeutic use | Denosumab | Absorptiometry, Photon | Genetic Markers - immunology | Osteoclasts - metabolism | Osteoporosis, Postmenopausal - drug therapy | Randomized Controlled Trials as Topic | Bone Density - drug effects | Quinazolines - therapeutic use | Aged | Osteoblasts - metabolism | Intercellular Signaling Peptides and Proteins - immunology | Osteoporosis | Complications and side effects | Care and treatment | Diagnosis | Bones | Vitamin D | Womens health | Metabolic disorders | Cathepsin K | Cytokines | Proteinase | Socio-economic aspects | SOST protein | Osteoblasts | Post-menopause | Bone resorption | NF- Kappa B protein | Bone mass | Fractures | Reviews | Aging | Monoclonal antibodies | Osteoclasts | Dkk1 protein | Osteogenesis | Communication
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 5/2015, Volume 141, Issue 5, pp. 909 - 921
Vascular endothelial growth factor signaling pathway plays a crucial role in angiogenesis and has become a promising target for cancer drug development. We... 
Angiogenesis | Medicine & Public Health | Hematology | Antibody | Tyrosine kinase inhibitor | Non-small cell lung cancer | Oncology | Cancer Research | Internal Medicine | 1ST-LINE TREATMENT | CONTROLLED-TRIAL | PLACEBO | BEVACIZUMAB | RANDOMIZED-PHASE-II | TYROSINE KINASE INHIBITORS | ONCOLOGY | DOUBLE-BLIND | 2ND-LINE TREATMENT | VANDETANIB PLUS DOCETAXEL | GROWTH-FACTOR | Niacinamide - analogs & derivatives | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - metabolism | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Odds Ratio | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Non-Small-Cell Lung - metabolism | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Thrombocytopenia - chemically induced | Randomized Controlled Trials as Topic | Disease-Free Survival | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Indoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Hemorrhage - chemically induced | Lung cancer, Small cell | Development and progression | Angiogenesis inhibitors | Lung cancer, Non-small cell | Analysis
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 12, pp. CD007927 - CD007927
Background This is an update of a previously published version of the review (Issue 10, 2011). Epithelial ovarian cancer (EOC) is the seventh most common cause... 
Erlotinib Hydrochloride | Management of advanced disease | Neoplasm Recurrence, Local | Antineoplastic Agents | Antibodies, Monoclonal | Quinazolines | ErbB Receptors | Randomized Controlled Trials as Topic | Gynaecology | Antibodies, Monoclonal, Humanized | Ovary | Chemotherapy | Deoxycytidine | Gynaecological | CANCER OF THE OVARY | Piperidines | Progression‐Free Survival | Quality of Life | Ovarian Neoplasms | Medicine General & Introductory Medical Sciences | Cancer | PEGYLATED LIPOSOMAL DOXORUBICIN | PLATINUM-RESISTANT OVARIAN | Antineoplastic Agents [therapeutic use] | Humans | FALLOPIAN-TUBE CANCER | Ovarian Neoplasms [drug therapy] | MONOCLONAL-ANTIBODY | Deoxycytidine [analogs & derivatives; therapeutic use] | Disease-Free Survival | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | PHARMACODYNAMIC TRIAL | Antibodies, Monoclonal [therapeutic use] | Receptor, Epidermal Growth Factor [antagonists & inhibitors] | Neoplasm Recurrence, Local [drug therapy] | Female | PRIMARY PERITONEAL CARCINOMA | TYROSINE KINASE INHIBITOR | RECURRENT EPITHELIAL OVARIAN | CLINICAL ACTIVITY | Antibodies, Monoclonal, Humanized - adverse effects | Erlotinib Hydrochloride - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | ErbB Receptors - antagonists & inhibitors | Antibodies, Monoclonal - adverse effects | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - mortality | Deoxycytidine - therapeutic use | Antineoplastic Agents - adverse effects | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Progression-Free Survival | Quinazolines - adverse effects | Erlotinib Hydrochloride - therapeutic use | Ovarian Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article